Table 5.

Most frequently reported adverse events^* in a) the single-dose study and b) the multiple dose study.

a) Single-dose study (2.5–500 mg omapatrilat)
Adverse event	Placebo (n = 21)	Omapatrilat 2.5–75 mg (n = 24)	Omapatrilat 125–500 mg (n = 18)
Tachycardia	1	0	2
Fatigue (Lethargy)	0	0	2
Headache	2	4	4
Dizziness	0	0	4
Flushing	0	0	7
Sensation of warmth	0	1	4

b) Multiple-dose study (10–125 mg omapatrilat).
Adverse event	Placebo (n = 21)	Omapatrilat 10–75 mg (n = 36)	Omapatrilat 125 mg (n = 6)
Orthostatic tachycardia	1	8	3
Fatigue (Lethargy)	0	1	3
Headache	2	3	4
Dizziness	0	3	3
Flushing	0	0	1
Sensation of warmth	0	1	0
Rash	0	0	1

^*Number of events: a single subject may have reported more than one event.